How To Achieve Late-Phase Success In Complex Oral Solid Dose Development

For oral solid dosage formulations, the transition from late-phase development to commercial scale is where scientific promise either holds or fractures. The decisions made during this period, from anchoring critical quality attributes to selecting granulation methods and manufacturing modes, carry consequences that ripple through validation, tech transfer, and regulatory submission.

This white paper presents a structured framework for approaching OSD scale-up with manufacturability as a design principle rather than an afterthought. It examines how predictive tools like in silico modeling and Design of Experiments can reduce late-phase uncertainty, how batch versus continuous manufacturing decisions interact with product complexity, and how containment and material standardization protect against revalidation risk, particularly for highly potent compounds.

The paper also addresses what to look for in a CDMO partnership when global infrastructure, regulatory depth, and integrated technical capabilities are essential to commercialization. Explore the full framework to assess your scale-up strategy.